Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
37 hedge funds and large institutions have $65.1M invested in Dicerna Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 8 closing their positions.
78% more capital invested
Capital invested by funds: $36.7M → $65.1M (+$28.5M)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
3% more funds holding
Funds holding: 36 → 37 (+1)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$1.2M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$691K |
| 3 |
Goldman Sachs
New York
|
+$384K |
| 4 |
MC
Matisse Capital
Portland,
Oregon
|
+$364K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$351K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.2M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$602K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$507K |
| 4 |
6CM
683 Capital Management
New York
|
-$145K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$37.5K |
DRNA Hedge Fund Activity: Q3 2017 in Review
37 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q3 2017, worth a combined $65.1M — up 78% from $36.7M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new DRNA positions and 8 closed out — a net gain of 1 holder — while 8 added to existing stakes and 10 trimmed.
The largest buyer was UBS Group, adding an estimated $1.2M. The largest seller was Fidelity Investments, cutting an estimated $3.2M.
- 37 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q3 2017, up from 36 in Q2 2017.
- Funds reported $65.1M of Dicerna Pharmaceuticals, Inc. stock for Q3 2017, up 78% quarter-over-quarter.
- 9 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q3 2017 and 8 closed out, a net change of +1 holder.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q3 2017 was UBS Group, an estimated $1.2M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q3 2017 was Fidelity Investments, an estimated $3.2M sold.
Based on aggregated 13F filings for Q3 2017.